# DPP-4 Inhibition, Incretins and Islet Function

> **NCT02089438** · PHASE4 · COMPLETED · sponsor: **Lund University** · enrollment: 24 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Saxagliptin
- **DRUG:** Vildagliptin
- **DRUG:** Sitagliptin

## Key facts

- **NCT ID:** NCT02089438
- **Lead sponsor:** Lund University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2017-06
- **Final completion:** 2017-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02089438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02089438, "DPP-4 Inhibition, Incretins and Islet Function". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02089438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*